CD4 and Parkinson disease: Removal of receptors for T cells, CD4, or the use of fingolimod (a compound that inhibits the migration of T cells from lymph nodes into the CNS) reduced the myeloid response and protected against the loss of dopaminergic cells, indicating the potential of targeted therapy in modifying Parkinson’s disease [64].